After 10 years of approval by the FDA of the first anti-VEGF drug, bevacizumab, resistance to anti-VEGF therapy remains a challenge in the treatment of cancer patients, revealing the need to explore alternative strategies to classical anti-angiogenic therapies, to obtain a durable therapeutic effect. Here, VEGFA is linked to cancer.